中国防痨杂志 ›› 2020, Vol. 42 ›› Issue (8): 863-868.doi: 10.3969/j.issn.1000-6621.2020.08.016
收稿日期:
2020-03-23
出版日期:
2020-08-10
发布日期:
2020-08-10
通信作者:
陈颖盈
E-mail:yingying.chen@shsmu.edu.cn
基金资助:
YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying(), WANG Ying
Received:
2020-03-23
Online:
2020-08-10
Published:
2020-08-10
Contact:
CHEN Ying-ying
E-mail:yingying.chen@shsmu.edu.cn
摘要:
结核病是目前全球死亡率最高的单一感染性疾病。卡介苗(bacille Calmette-Guérin,BCG)作为唯一的预防性疫苗,在包括中国在内的结核病高危地区的新生儿出生时即被接种,在结核病防控中发挥了重要作用。然而,近年来的研究结果显示,BCG的保护力具有一定的时效性,尤其在成年人中保护力明显减弱。因此,如何改造BCG以增强其抗结核免疫保护作用将成为结核病疫苗研发和结核病防控的重点研究方向之一。作者复习相关文献,从BCG的改造和接种两方面论述BCG的研究现状和未来应用策略。
杨鲁琦, 沈鸣逸, 沙巍, 陈颖盈, 王颖. 卡介苗的免疫保护机制及其改造策略进展[J]. 中国防痨杂志, 2020, 42(8): 863-868. doi: 10.3969/j.issn.1000-6621.2020.08.016
YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying. Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868. doi: 10.3969/j.issn.1000-6621.2020.08.016
[1] | World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization, 2019. |
[2] |
Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016,13(10):e1002152. doi: 10.1371/journal.pmed.1002152.
doi: 10.1371/journal.pmed.1002152 URL pmid: 27780211 |
[3] |
World Health Organization. BCG vaccines: WHO positon paper-February 2018. Wkly Epidemiol Rec, 2018,93(8):73-96.
URL pmid: 29474026 |
[4] | World Health Organization. SAGE evidence to recommendations framework. Geneva:World Health Organization, 2017. |
[5] |
Nieuwenhuizen NE, Kaufmann SHE. Next-Generation Vaccines Based on Bacille Calmette-Guérin. Front Immunol, 2018,9:121. doi: 10.3389/fimmu.2018.00121.
doi: 10.3389/fimmu.2018.00121 URL pmid: 29459859 |
[6] | Ravenel MP. La Vaccination Préventive Contre la Tuberculose par le “BCG”. Am J Public Health Nations Health, 1928,18(8):1075. |
[7] | Chen ZR, Wei XH, Zhu ZY. BCG in China. Chin Med J (Engl), 1982,95(6):437-442. |
[8] |
Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis, 2014,58(4):470-480. doi: 10.1093/cid/cit790.
doi: 10.1093/cid/cit790 URL |
[9] |
Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol, 2014,15(10):895-899. doi: 10.1038/ni.2961.
doi: 10.1038/ni.2961 URL |
[10] |
Sugisaki K, Dannenberg AM Jr, Abe Y, et al. Nonspecific and immune-specific up-regulation of cytokines in rabbit dermal tuberculous (BCG) lesions. J Leukoc Biol, 1998,63(4):440-450. doi: 10.1002/jlb.63.4.440.
doi: 10.1002/jlb.63.4.440 URL pmid: 9544573 |
[11] |
Tsuji S, Matsumoto M, Takeuchi O, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun, 2000,68(12):6883-6890. doi: 10.1128/iai.68.12.6883-6890.2000.
doi: 10.1128/iai.68.12.6883-6890.2000 URL pmid: 11083809 |
[12] |
Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A, 2012,109(43):17537-17542. doi: 10.1073/pnas.1202870109.
doi: 10.1073/pnas.1202870109 URL pmid: 22988082 |
[13] |
Turner J, Dockrell HM. Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology, 1996,87(3):339-342. doi: 10.1046/j.1365-2567.1996.512590.x.
doi: 10.1046/j.1365-2567.1996.512590.x URL pmid: 8778016 |
[14] |
Brown RM, Cruz O, Brennan M, et al. Lipoarabinomannan-reactive human secretory immunoglobulin A responses induced by mucosal bacille Calmette-Guérin vaccination. J Infect Dis, 2003,187(3):513-517. doi: 10.1086/368096.
URL pmid: 12552438 |
[15] |
Hamasur B, Haile M, Pawlowski A, et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine, 2003,21(25/26):4081-4093. doi: 10.1016/s0264-410×(03)00274-3.
doi: 10.1016/S0264-410X(03)00274-3 URL |
[16] | World Health Organization. WHO preferred product characteristics for new tuberculosis vaccines. Geneva: World Health Organization, 2018. |
[17] |
Zhang L, Ru HW, Chen FZ, et al. Variable Virulence and Efficacy of BCG Vaccine Strains in Mice and Correlation with Genome Polymorphisms. Mol Ther, 2016,24(2):398-405. doi: 10.1038/mt.2015.216.
doi: 10.1038/mt.2015.216 URL pmid: 26643797 |
[18] |
Nguipdop-Djomo P, Heldal E, Rodrigues LC, et al. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis, 2016,16(2):219-226. doi: 10.1016/S1473-3099(15)00400-4.
doi: 10.1016/S1473-3099(15)00400-4 URL pmid: 26603173 |
[19] |
Kirman JR, Henao-Tamayo MI, Agger EM. The Memory Immune Response to Tuberculosis. Microbiol Spectr, 2016,4(6). doi: 10.1128/microbiolspec.TBTB2-0009-2016.
doi: 10.1128/microbiolspec.MCHD-0050-2016 URL pmid: 28087931 |
[20] |
Orme IM. The Achilles heel of BCG. Tuberculosis (Edinb), 2010,90(6):329-332. doi: 10.1016/j.tube.2010.06.002.
doi: 10.1016/j.tube.2010.06.002 URL |
[21] |
Lindenstrøm T, Knudsen NP, Agger EM, et al. Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1-IL-2-secreting central memory cells. J Immunol, 2013,190(12):6311-6319. doi: 10.4049/jimmunol.1300248.
doi: 10.4049/jimmunol.1300248 URL pmid: 23677471 |
[22] |
Jurado JO, Alvarez IB, Pasquinelli V, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol, 2008,181(1):116-125. doi: 10.4049/jimmunol.181.1.116.
doi: 10.4049/jimmunol.181.1.116 URL pmid: 18566376 |
[23] |
Cruz A, Torrado E, Carmona J, et al. BCG vaccination-induced long-lasting control of Mycobacterium tuberculosis correlates with the accumulation of a novel population of CD4+IL-17+TNF+IL-2+ T cells. Vaccine, 2015,33(1):85-91. doi: 10.1016/j.vaccine.2014.11.013.
doi: 10.1016/j.vaccine.2014.11.013 URL pmid: 25448107 |
[24] |
Connor LM, Harvie MC, Rich FJ, et al. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur J Immunol, 2010,40(9):2482-2492. doi: 10.1002/eji.200940279.
doi: 10.1002/eji.200940279 URL pmid: 20602436 |
[25] |
Kaveh DA, Garcia-Pelayo MC, Hogarth PJ. Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis. Vaccine, 2014,32(51):6911-6918. doi: 10.1016/j.vaccine.2014.10.041.
doi: 10.1016/j.vaccine.2014.10.041 URL pmid: 25444816 |
[26] |
Minassian AM, Satti I, Poulton ID, et al. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis, 2012,205(7):1035-1042. doi: 10.1093/infdis/jis012.
doi: 10.1093/infdis/jis012 URL |
[27] |
Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020,577(7788):95-102. doi: 10.1038/s41586-019-1817-8.
doi: 10.1038/s41586-019-1817-8 URL pmid: 31894150 |
[28] |
Derrick SC, Kolibab K, Yang A, et al. Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice. Clin Vaccine Immunol, 2014,21(10):1443-1451. doi: 10.1128/CVI.00394-14.
doi: 10.1128/CVI.00394-14 URL |
[29] |
Manjaly Thomas ZR, McShane H. Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg, 2015,109(3):175-181. doi: 10.1093/trstmh/tru206.
doi: 10.1093/trstmh/tru206 URL pmid: 25636950 |
[30] |
Oxlade O, Murray M. Tuberculosis and poverty: why are the poor at greater risk in India? PLoS One, 2012,7(11):e47533. doi: 10.1371/joural.pone.0047533.
doi: 10.1371/journal.pone.0047533 URL pmid: 23185241 |
[31] |
Olmos P, Donoso J, Rojas N, et al. Tuberculosis and diabetes mellitus: a longitudinal-retrospective study in a teaching hospital. Rev Med Chil, 1989,117(9):979-983.
URL pmid: 2519480 |
[32] |
Zhu B, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology, 2018,23(4):359-368. doi: 10.1111/resp.13245.
doi: 10.1111/resp.13245 URL pmid: 29341430 |
[33] |
Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science, 1999,284(5419):1520-1523. doi: 10.1126/science.284.5419.1520.
doi: 10.1126/science.284.5419.1520 URL pmid: 10348738 |
[34] |
Brandt L, Elhay M, Rosenkrands I, et al. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun, 2000,68(2):791-795. doi: 10.1128/iai.68.2.791-795.2000.
doi: 10.1128/iai.68.2.791-795.2000 URL pmid: 10639447 |
[35] |
Pym AS, Brodin P, Brosch R, et al. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol, 2002,46(3):709-717. doi: 10.1046/j.1365-2958.2002.03237.x.
doi: 10.1046/j.1365-2958.2002.03237.x URL pmid: 12410828 |
[36] |
Roche PW, Winter N, Triccas JA, et al. Expression of Mycobacterium tuberculosis MPT64 in recombinant Myco. smegmatis: purification, immunogenicity and application to skin tests for tuberculosis. Clin Exp Immunol, 1996,103(2):226-232. doi: 10.1046/j.1365-2249.1996.d01-613.x.
doi: 10.1046/j.1365-2249.1996.d01-613.x URL pmid: 8565304 |
[37] |
Dhar N, Rao V, Tyagi AK. Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Med Microbiol Immunol, 2004,193(1):19-25. doi: 10.1007/s00430-002-0170-x.
doi: 10.1007/s00430-002-0170-x URL pmid: 12905016 |
[38] |
Chen Y, Xiao JN, Li Y, et al. Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against Mycobacterium tuberculosis Infection. Front Immunol, 2019,9:3190. doi: 10.3389/fimmu.2018.03190.
doi: 10.3389/fimmu.2018.03190 URL pmid: 30700988 |
[39] |
Becker K, Sander P. Mycobacterium tuberculosis lipoproteins in virulence and immunity-fighting with a double-edged sword. FEBS Lett, 2016,590(21):3800-3819. doi: 10.1002/1873-3468.12273.
doi: 10.1002/1873-3468.12273 URL pmid: 27350117 |
[40] |
Clemens DL, Lee BY, Horwitz MA. Purification, characteri-zation, and genetic analysis of Mycobacterium tuberculosis urease, a potentially critical determinant of host-pathogen interaction. J Bacteriol, 1995,177(19):5644-5652. doi: 10.1128/jb.177.19.5644-5652.1995.
doi: 10.1128/jb.177.19.5644-5652.1995 URL pmid: 7559354 |
[41] |
Vogelzang A, Perdomo C, Zedler U, et al. Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guérin ΔureC::hly vaccine’s superior protection against tuberculosis . J Infect Dis, 2014,210(12):1928-1937. doi: 10.1093/infdis/jiu347.
doi: 10.1093/infdis/jiu347 URL pmid: 24943726 |
[42] |
Grode L, Ganoza CA, Brohm C, et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine, 2013,31(9):1340-1348. doi: 10.1016/j.vaccine.2012.12.053.
doi: 10.1016/j.vaccine.2012.12.053 URL pmid: 23290835 |
[43] |
Loxton AG, Knaul JK, Grode L, et al. Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol, 2017,24(2):e00439-16. doi: 10.1128/CVI.00439-16.
doi: 10.1128/CVI.00439-16 URL pmid: 27974398 |
[44] |
Sun R, Skeiky YA, Izzo A, et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine, 2009,27(33):4412-4423. doi: 10.1016/j.vaccine.2009.05.048.
doi: 10.1016/j.vaccine.2009.05.048 URL pmid: 19500523 |
[45] |
Hoft DF, Blazevic A, Selimovic A, et al. Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial. EBioMedicine, 2016,7:278-286. doi: 10.1016/j.ebiom.2016.04.010.
doi: 10.1016/j.ebiom.2016.04.010 URL pmid: 27322481 |
[46] | 赵爱华, 徐苗, 王国治. 新一代抗结核分枝杆菌疫苗将会建立在现用卡介苗的基础上吗? 微生物与感染, 2017,12(4):206-210. doi: 10.3969/j.issn.1673-6184.2017.04.004. |
[47] |
卢锦标, 赵爱华, 王国治, 等. 对我国结核病免疫预防策略的探讨. 中国防痨杂志, 2014,36(11):927-929. doi: 10.3969/j.issn.1000-6621.2014.11.001.
doi: 10.3969/j.issn.1000-6621.2014.11.001 URL |
[48] | 卢锦标, 赵爱华, 王国治, 等. 结核病新疫苗临床研究进展. 中华结核和呼吸杂志, 2019,42(10):783-790. doi: 10.3760/cma.j.issm.1001-0939.2019.10.015. |
[49] |
Lerm M, Netea MG. Trained immunity: a new avenue for tuberculosis vaccine development. J Intern Med, 2016,279(4):337-346. doi: 10.1111/joim.12449.
doi: 10.1111/joim.12449 URL pmid: 26602369 |
[50] |
Madan M, Pahuja S, Mohan A, et al. TB infection and BCG vaccination: are we protected from COVID-19? Public health, 2020,185:91-92. doi: 10.1016/j.puhe.2020.05.042.
doi: 10.1016/j.puhe.2020.05.042 URL pmid: 32590235 |
[1] | 刘晓莉, 雷丽梅, 郭周莉, 黄殷, 徐静, 赵霞, 王燕, 付莉. 结核病患者产生病耻感与领悟社会支持的相关性研究[J]. 中国防痨杂志, 2020, 42(9): 1002-1008. |
[2] | 中国防痨协会学术工作委员会《中国防痨杂志》编辑委员会. 抗结核药品固定剂量复合制剂的临床使用专家共识[J]. 中国防痨杂志, 2020, 42(9): 885-893. |
[3] | 靳鸿建. 我国县级结核病防治服务体系建设及防治工作亟需加强——一位老防痨工作者的意见和建议[J]. 中国防痨杂志, 2020, 42(9): 896-902. |
[4] | 张灿有, 夏辉, 成君. Ⅱ级生物安全柜在结核病实验室中的检测及报告要求[J]. 中国防痨杂志, 2020, 42(9): 903-909. |
[5] | 周林, 刘二勇, 孟庆琳, 陈明亭, 周新华, 高微微, 林明贵, 谢汝明. 《WS 288—2017 肺结核诊断》标准实施后肺结核诊断质量评估分析[J]. 中国防痨杂志, 2020, 42(9): 910-915. |
[6] | 刘二勇, 王前, 周林, 张国钦, 张修磊, 马永成, 杨枢敏, 王毳, 孟庆琳, 陈明亭, 林明贵, 屠德华. 我国部分地区病原学检测阴性肺结核诊断质量现状分析[J]. 中国防痨杂志, 2020, 42(9): 916-920. |
[7] | 孟庆琳, 李进岚, 林定文, 马永成, 侯双翼, 刘年强, 周林. 结核病防治从业人员对新的结核病标准相关知识知晓情况调查分析[J]. 中国防痨杂志, 2020, 42(9): 921-925. |
[8] | 王前, 周林, 刘二勇, 赵雁林, 李涛, 陈明亭, 杨丽佳, 王嘉. 我国县级结核病定点医疗机构结核病诊断能力现况调查研究[J]. 中国防痨杂志, 2020, 42(9): 926-930. |
[9] | 李婷, 何金戈, 苏茜, 李京, 李运葵, 高文凤, 高媛, 杨文. 结核菌素试验在四川省布拖县HIV感染/AIDS患者中筛查结核感染的价值[J]. 中国防痨杂志, 2020, 42(9): 931-936. |
[10] | 李运葵, 何金戈, 苏茜, 李婷, 李京, 高文凤, 杨文, 毛光玉. 结核病症状筛查在四川省布拖县HIV感染/AIDS患者中发现结核病患者的价值[J]. 中国防痨杂志, 2020, 42(9): 937-941. |
[11] | 苏茜, 夏勇, 逯嘉, 王丹霞, 何金戈. 2009—2018年四川省0~14 岁儿童肺结核流行特征分析[J]. 中国防痨杂志, 2020, 42(9): 942-947. |
[12] | 邓亚丽, 张天华, 刘卫平, 张宏伟, 马煜, 李鹏. 2014—2018年陕西省肺结核发病的时空聚集性分析[J]. 中国防痨杂志, 2020, 42(9): 948-955. |
[13] | 董晓, 赵珍, 刘年强, 王森路, 崔燕. 2009—2017年新疆维吾尔自治区老年肺结核发现特征分析[J]. 中国防痨杂志, 2020, 42(9): 956-961. |
[14] | 马廷龙, 韩毅, 程序, 刘志东. 超声抗结核药品电导入联合化疗对胸壁结核的疗效观察[J]. 中国防痨杂志, 2020, 42(9): 968-972. |
[15] | 南海, 张芸, 杨新婷, 段鸿飞. GeneXpert MTB/RIF对骨关节结核诊断价值的Meta分析[J]. 中国防痨杂志, 2020, 42(9): 973-980. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||